Compras y ventas de directivos de Intuitive Surgical (ISRG)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de Intuitive Surgical, Inc. (ISRG): ninguna compra y 71 ventas
169 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de Intuitive Surgical, Inc. entre el 2025-09-02 y el 2026-10-13 (histórico de 15 meses): 0 compras y 71 ventas en mercado abierto, y 98 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $17,3M de Guthart Gary S el 2025-10-24.
Compras y ventas de directivos de Intuitive Surgical en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de Intuitive Surgical declararon 68 ventas por $93,3M en mercado abierto, y ninguna compra.
Quien más vendió fue Guthart Gary S (Consejero): $48,8M en 4 ventas, de 12 vendedores distintos.
La mayor operación del período fue una venta de $17,3M el 24 oct 2025, de Guthart Gary S (Executive Chair of the Board o), dentro de un plan 10b5-1. Formulario 4 en sec.gov (0001280628-25-000004).
Las 68 ventas llevan en el Formulario 4 la marca de plan 10b5-1: todas estaban programadas con meses de antelación.
En los tres últimos meses hay 19 ventas, frente a 15 en los tres anteriores. La última venta es del 15 sept 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. Intuitive Surgical tiene más ventas que 58 de las otras 58, es la 9.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como ISRG no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 169 operaciones de ISRG en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2025-10-24 | 2025-10-27 | Guthart Gary S | Executive Chair of the Board o | $17,3M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: Trust FBO Daughter; Trust FBO Son 4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $541.76 to $550.16 as follows: 800 shares sold at $541.76 to $542.59; 1,000 shares sold at $542.89 to $543.22; 2,563 shares sold at $544 to $545; 1,600 shares sold at $545.33 to $546.29; 2,770 shares sold at $546.34 to $547.19; 7,383 shares sold at $547.35 to $548.31; 9,068 shares sold at $548.36 to $549.35; and 3,616 shares sold at $549.485 to $550.16. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.74 to $548.48 as follows: 100 shares sold at $542.74; 205 shares sold at $543.97 to $544.45; 250 shares sold at $545.06 to $545.94; 200 shares sold at $546.46 to $546.75; and 645 shares sold at $547.49 to $548.48. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $548.45 as follows: 190 shares sold at $542.16 to $542.98; 150 shares sold at $543.79 to $544.30; 190 shares sold at $545.00 to $545.33; 292 shares sold at $546.34 to $547.20; and 578 shares sold at $547.51 to $548.45. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2026-01-27 | 2026-01-28 | Guthart Gary S | Consejero | $14,5M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: Trust FBO Daughter; Trust FBO Son 4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $525.51 to $534.00 as follows: 2,500 shares sold at $525.51 to $525.71; 280 shares sold at $526.94 to $527.41; 2,252 shares sold at $528.23 to $529.18; 9,860 shares sold at $529.27 to $530.27; 3,475 shares sold at $530.29 to $531.22; 1,589 shares sold at $531.37 to $532.24; 3,704 shares sold at $532.53 to $533.41; and 840 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 298 shares sold at $530.98 to $531.87; 302 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 360 shares sold at $530.98 to $531.86; 240 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-08-29 | 2025-09-02 | Guthart Gary S | Executive Chair of the Board o | $13,9M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $469.04 to $475.40 as follows: 5,200 shares sold at $469.04 to $470.03; 3,440 shares sold at $470.21 to $471.17; 4,400 shares sold at $471.38 to $472.38; 6,194 shares sold at $472.64 to $473.60; 7,921 shares sold at $473.79 to $474.72; and 2,205 shares sold at $475.00 to $475.40. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-10-24 | 2025-10-27 | Rosa David J. | Chief Executive Officer (CEO) | $13,4M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 11, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $550.21 as follows: 1,075 shares sold at $542.16 to $543.10; 1,000 shares sold at $543.23 to $544.22; 1,830 shares sold at $544.30 to $545.06; 1,300 shares sold at $545.33 to $546.15; 2,346 shares sold at $546.34 to $547.30; 6,919 shares sold at $547.37 to $548.37; 7,257 shares sold at $548.40 to $549.40; and 2,773 shares sold at $549.42 to $550.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-12-01 | 2025-12-02 | Guthart Gary S | Executive Chair of the Board o | $13,0M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $568.62 to $573.54 as follows: 5,550 shares sold at $568.62 to $569.62; 6,304 shares sold at $569.64 to $570.63; 2,285 shares sold at $570.66 to $571.61; 5,528 shares sold at $571.70 to $572.70; 3,139 shares sold at $572.72 to $573.54. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-11-12 | 2025-11-13 | Charlton Henry L | EVP & Chief Commercial and Mkt | $8,0M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 1, 2026. | SEC |
| 2025-10-28 | 2025-10-29 | Curet Myriam | EVP & Chief Medical Officer | $4,1M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $545.57 to $551.71 as follows: 1,173 shares sold at $545.57 to $546.54; 2,460 shares sold at $546.69 to $547.63; 314 shares sold at $547.72 to $548.68; 2,610 shares sold at $549.26 to $550.21; 1,000 shares sold at $550.39 to $551.04; 5 shares sold at $551.71. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2026-08-11 | 2026-08-12 | Guthart Gary S | Consejero | $4,0M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 15, 2027. | SEC |
| 2025-12-12 | 2025-12-15 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $2,5M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. | SEC |
| 2026-06-01 | 2026-06-02 | Jeddi Iman | SVP & GM da Vinci Platforms & | $2,4M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 5, 2026. | SEC |
| 2026-03-03 | 2026-03-03 | Curet Myriam | EVP & Chief Medical Officer | $2,3M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. | SEC |
| 2025-11-10 | 2025-11-12 | Miller Brian Edward | EVP & Chief Digital Officer | $2,0M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on December 10, 2025. | SEC |
| 2025-10-24 | 2025-10-27 | Barratt Craig H | Consejero | $1,2M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. | SEC |
| 2026-03-04 | 2026-03-05 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $1,2M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $495.19 to $500.00 as follows: 648 shares sold at $495.19 and 1,714 shares sold at $500.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2026-02-27 | 2026-03-02 | Curet Myriam | EVP & Chief Medical Officer | $1,2M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. | SEC |
| 2025-11-05 | 2025-11-06 | Widman Fredrik | VP Corporate Controller | $1,1M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 21, 2026. | SEC |
| 2025-11-12 | 2025-11-13 | Barratt Craig H | Consejero | $435k | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. | SEC |
| 2026-09-15 | 2026-09-16 | Widman Fredrik | VP Corporate Controller | $408k | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on September 15, 2027. | SEC |
| 2026-03-05 | 2026-03-05 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $321k | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. | SEC |
| 2026-03-06 | 2026-03-10 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $318k | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 2 sept 2025 y el 13 oct 2026 no consta ni una compra en mercado abierto de Intuitive Surgical, Inc.: 71 ventas por $107,4M y cero dólares comprados.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de Intuitive Surgical, Inc. salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| S | Venta en mercado abierto | 71 | $107,4M |
| M | Ejercicio de opciones | 63 | $23,1M |
| F | Retención fiscal (acciones entregadas por impuestos) | 32 | $33,4M |
| G | Regalo o donación | 2 | $0 |
| J | Otra operación (explicada en el propio filing) | 1 | $0 |
| Total | Todo lo declarado en el período | 169 | $163,9M |
43 de las 169 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de Intuitive Surgical, Inc. 20 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 12 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 12 que vendieron en mercado abierto (71 ventas en total), los tres que más vendieron suman $84,5M de los $107,4M: el 79% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Guthart Gary S | Consejero | 15 | — | $62,7M (5) | 2026-08-12 |
| Rosa David J. | Chief Executive Officer (CEO) | 11 | — | $13,4M (1) | 2026-07-13 |
| Curet Myriam | EVP & Chief Medical Officer | 28 | — | $8,4M (13) | 2026-03-11 |
| Charlton Henry L | EVP & Chief Commercial and Mkt | 8 | — | $8,0M (1) | 2026-03-02 |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 39 | — | $5,7M (32) | 2026-09-11 |
| Jeddi Iman | SVP & GM da Vinci Platforms & | 8 | — | $2,4M (1) | 2026-06-02 |
| Miller Brian Edward | EVP & Chief Digital Officer | 2 | — | $2,0M (1) | 2025-11-12 |
| Widman Fredrik | VP Corporate Controller | 13 | — | $1,8M (5) | 2026-09-16 |
Se enseñan los 8 que más dinero movieron, de 20. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue mar 2026: 0 compras y 9 ventas, por $4,9M. 1 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 1 | $13,9M |
| sept 2025 | 0 | $0 | 2 | $306k |
| oct 2025 | 0 | $0 | 5 | $36,1M |
| nov 2025 | 0 | $0 | 5 | $11,6M |
| dic 2025 | 0 | $0 | 6 | $16,1M |
| ene 2026 | 0 | $0 | 3 | $14,7M |
| feb 2026 | 0 | $0 | 6 | $1,7M |
| mar 2026 | 0 | $0 | 9 | $4,9M |
| abr 2026 | 0 | $0 | 2 | $292k |
| may 2026 | 0 | $0 | 6 | $218k |
| jun 2026 | 0 | $0 | 7 | $2,6M |
| jul 2026 | 0 | $0 | 5 | $49k |
| ago 2026 | 0 | $0 | 9 | $4,5M |
| sept 2026 | 0 | $0 | 5 | $450k |
| oct 2026 | 0 | $0 | 0 | $0 |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de Intuitive Surgical, Inc. (ISRG) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
20 de las 20 ventas de la tabla van marcadas como programadas (plan 10b5-1): se firman con meses de antelación y se ejecutan solas, así que no dicen lo que el directivo piensa hoy. Intuitive Surgical no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 13 oct 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
20 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.